Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance.

"We are proud to be again designated Supersector leader in healthcare in the Dow Jones Sustainability Index. This top ranking is a reflection of Roche's commitment to its employees, communities and the environment. Sustainable corporate policies and practices ultimately create long-term value for our stakeholders and promote innovation," said Severin Schwan, CEO of Roche. "Over the past year we have made progress on our diversity and energy goals as well as introduced new programmes to increase access to our products in developing countries. Our ongoing leadership position will further encourage us to drive these programmes while continuing to discover and develop innovative medicines and diagnostic solutions for patients with unmet medical needs."

Some of Roche's efforts emphasized in this year's DJSI assessment were Roche's programmes focused on attracting and retaining talent, developing future leaders as well as environmental management and reporting. In addition, managing innovation along with our contribution to improving patient health outcomes was highlighted.

In 2009 Roche defined five-year corporate goals, with Key Performance Indicators enabling it to measure the progress. Amongst them, Roche introduced a diversity objective to increase the percentage of women in key positions by at least 50 percent, plus an energy efficiency goal of a 10 percent reduction in energy consumption by end 2014.

About the Dow Jones Sustainability Indexes (DJSI)
The DJSI is the most widely accepted global assessment of how companies approach their social, economic and environmental responsibility. Annual selection into the DJSI World and DJSI Europe follows a thorough analysis of corporate economic, environmental and social performance by Sustainable Asset Management (SAM), an investment specialist group focused exclusively on sustainability investment strategies. They assess business management practices such as corporate governance, risk management, human resource practices, customer relations, stakeholder engagement and the quality of environmental reporting, in addition to sector-specific elements, such as strategies on access to medicines and innovation in R&D. Roche has been included in the DJSI World and Europe since 2004, and was named Supersector Leader in healthcare in 2009 and again in 2010.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...